Regenerative medicine company, Regeneus Ltd (ASX:RGS), announces changes to its Board and senior management team consistent with its focus on increasing commercial and partnering activities for its regenerative medicine products, reducing costs and greater Board independence.
Regenerative medicine company Orthocell Limited (ASX:OCC) announced today its success in growing human tendons in a laboratory for the first time.
Regeneus Ltd (ASX:RGS) Presentation to Shareholders at AGM 2014 with significant achievements to date including the successful translation of 4 regenerative medicine technology platforms into products for musculoskeletal and oncology applications for humans and animals.
Together with the company's committed and capable management and staff, the Board is intent on realising Regeneus' full potential, not only to deliver significant benefits to both human and animal health but also to justify shareholders' faith in Regeneus through enhancing the value of your investment in the company.
Avita Medical Ltd. (ASX:AVH), (OTCMKTS:AVMXY) a regenerative medicine company specializing in the treatment of wounds, scars, and skin defects, today announced that ReCell(R) will feature prominently during the scientific programme of the International Society for Burn Injuries' (ISBI) 17th Biennial Congress, in Sydney, Australia, October 12th to 16th.
Regenerative medicine company Regeneus Ltd (ASX:RGS) wishes to officially respond to the ABC 7.30's Sell Therapy story, which aired on 6th October 2014.
Regeneus Ltd (ASX:RGS) is pleased to announce it has received $3.7m from the Australian Government's Research and Development Tax Incentive Program for activities conducted during the 2014 financial year.
